FDA Approves Foundation Medicine Blood Test as CDx For Rozlytrek
FoundationOne Liquid CDx, a liquid biopsy test, is the only blood-based CDx approved for the targeted cancer therapy.
Source: genomeweb.com
Genentech Tarceva News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Genentech Tarceva. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Genentech Tarceva Today - Breaking & Trending Today
FDA Approves Foundation Medicine Assay as CDx for Certain NSCLC Therapies
The FoundationOne Liquid CDx test can be used with Tarceva (erlotinib), Tagrisso (osimertinib), and Iressa (gefitinib), and other TKIs approved in the future.
Source: 360dx.com
FDA Approves Foundation Medicine Assay as CDx for Certain NSCLC Therapies
The FoundationOne Liquid CDx test can be used with Tarceva (erlotinib), Tagrisso (osimertinib), and Iressa (gefitinib), and other TKIs approved in the future.
Source: genomeweb.com
EGFR Exon 20 Insertion Location Could Be Key Factor in NSCLC Treatment
Data showing that the location of EGFR exon 20 insertion mutations impacts patients' responses to Spectrum's poziotinib could have implications for other EGFR inhibitors.
Source: precisiononcologynews.com
Theseus Pharmaceuticals Addressing KIT, EGFR Resistance With Pan-Variant Inhibitors
The company is conducting a clinical trial of a pan-variant inhibitor for KIT-mutant GIST and hopes to advance an EGFR pan-variant inhibitor to the clinic soon.
Source: precisiononcologynews.com